First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Darovasertib data are promised for the last week of March.
The company buys in a PI3Kα and mTOR combo.
Gilead opting against IDE397 is still good news for Ideaya.
Progression-free and overall survival data from Companion-002 are due this quarter.
JSKN027 will become the first ADC with this mechanism to enter human trials.
